Menu
Recruiting NCT04073420

Medtronic Cardiac Surgery PMCF Registry

Observational Valve Disease, Heart

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Surgical Heart Valve Repair Products, Surgical Heart Valve Replacement Products.
Who it may be relevant to
Registry conditions: Valve Disease, Heart. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States, Austria, Belgium, France, Germany +5
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Medtronic Cardiac Surgery Post Market Clinical Follow-up Registry

Overview

This registry is being conducted to support ongoing post-market surveillance activities.

Interventions

  • Device Surgical Heart Valve Repair Products
    Surgical heart valve repair products.
  • Device Surgical Heart Valve Replacement Products
    Surgical heart valve replacement products.

Primary outcome measures

  • Identify unique failure modes [Time frame: 10 years]
  • Identify trends in adverse device effects [Time frame: 10 years]

Eligibility criteria

Inclusion criteria

  • Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements
  • Patient has or is intended to receive or be treated with an eligible product
  • Patient is within enrollment window of treatment/therapy received at the time of their initial Registry enrollment, or meets criteria for retrospective enrollment

Exclusion criteria

  • Patient who is, or is expected to be, inaccessible for follow-up
  • Patient prohibited from participation by local law
  • Patient is currently enrolled in or plans to enroll in any concurrent investigational drug and/or device study that may confound results

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

United States · 11 centers
  • WellStar Kennestone Hospital — Marietta
  • University of Michigan — Ann Arbor
  • Mount Sinai Medical Center — New York
  • Saint Francis Hospital — Roslyn
  • Saint Josephs Hospital Health Center — Syracuse
  • Duke University Medical Center — Durham
  • University Hospitals Cleveland — Cleveland
  • University of Pittsburgh Medical Center UPMC Presbyterian — Pittsburgh
  • … and 3 more centers
Germany · 6 centers
  • Schüchtermann-Klinik — Bad Rothenfelde
  • Herzzentrum Dresden GmbH Universitätsklinik — Dresden
  • Universitätsklinikum Düsseldorf — Düsseldorf
  • Albertinen-Herz- und Gefäßzentrum — Hamburg
  • Herzzentrum Leipzig — Leipzig
  • Deutsches Herzzentrum München Klinik an der TU München — München
Italy · 2 centers
  • Ospedale Pasquinucci Massa — Massa
  • IRCCS Policlinico — San Donato
Austria · 1 center
  • Allgemeines Krankenhaus - Universitätskliniken Wien — Vienna
Belgium · 1 center
  • UZ Leuven — Leuven
France · 1 center
  • Hôpital Haut-Lévêque - CHU de Bordeaux — Pessac
Greece · 1 center
  • Onassis Cardiac Surgery Center — Athens
Netherlands · 1 center
  • Leids Universitair Medisch Centrum — Leiden
Spain · 1 center
  • Hospital Regional Universitario Carlos Haya Málaga - Hospital General — Málaga
Switzerland · 1 center
  • Inselspital - Universitätsspital Bern — Bern

Identifiers

NCT: NCT04073420 · MDT18061SUR003

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗